Attributable Risk Estimate of Severe Psoriasis on Major Cardiovascular Events

2011/07/25 by Nehal N. Mehta, Yiding Yu, YiDing Yu +5 · 28 citations
Immunology and Microbiology · Biochemistry, Genetics and Molecular Biology · Medicine · #Psoriasis: Treatment and Pathogenesis #Retinoids in leukemia and cellular processes #Spondyloarthritis Studies and Treatments

paper · doi:10.1016/j.amjmed.2011.03.028

Cited by

• The Emerging Role of IL-17 in the Pathogenesis of Psoriasis: Preclinical and Clinical Findings
• Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities
• 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension
• Chronic skin-specific inflammation promotes vascular inflammation and thrombosis. [europepmc]
• The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. [europepmc]
• The impact of psoriasis on 10-year Framingham risk. [europepmc]
• Metabolic syndrome in patients with psoriatic disease. [europepmc]
• Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis. [europepmc]
• IL-17 in psoriasis: implications for therapy and cardiovascular co-morbidities. [europepmc]
• Cardiovascular risk profile at the onset of psoriatic arthritis: a population-based cohort study. [europepmc]
• Chronic Psoriatic Skin Inflammation Leads to Increased Monocyte Adhesion and Aggregation. [europepmc]
• IL-17A, IL-22, IL-6, and IL-21 Serum Levels in Plaque-Type Psoriasis in Brazilian Patients. [europepmc]
• Severity of Psoriasis Associates With Aortic Vascular Inflammation Detected by FDG PET/CT and Neutrophil Activation in a Prospective Observational Study. [europepmc]
• Psoriasis and comorbid diseases: Epidemiology. [europepmc]
• Psoriasis as a human model of disease to study inflammatory atherogenesis. [europepmc]
• Coronary Plaque Characterization in Psoriasis Reveals High-Risk Features That Improve After Treatment in a Prospective Observational Study. [europepmc]
• Unraveling Vascular Inflammation: From Immunology to Imaging. [europepmc]
• Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences. [europepmc]
• Potential Immunological Links Between Psoriasis and Cardiovascular Disease. [europepmc]
• Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure. [europepmc]
• The role of the interleukin-23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis. [europepmc]
• Role of Neutrophils in Psoriasis. [europepmc]
• Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. [europepmc]
• CCL20 in psoriasis: A potential biomarker of disease severity, inflammation, and impaired vascular health. [europepmc]
• Cardiovascular Risk in Patients With Psoriasis: JACC Review Topic of the Week. [europepmc]
• Psoriasis Increased the Risk of Adverse Cardiovascular Outcomes: A New Systematic Review and Meta-Analysis of Cohort Study. [europepmc]
• The Association Between Psoriasis and Risk of Cardiovascular Disease: A Mendelian Randomization Analysis. [europepmc]
• Psoriasis and Cardiometabolic Diseases: Shared Genetic and Molecular Pathways. [europepmc]